TPN-101 Clinical Trial: for ALS & the C9orf72 Mutation - an Overview of the Trial plus Q&A @EverythingALS
TPN-101 Clinical Trial: for ALS & the C9orf72 Mutation - an Overview of the Trial plus Q&A @EverythingALS
Uploaded April 2022 | Updated September 2026, 2 weeks ago
Register to upcoming events
everythingals.org/events

Participate in our ALS Research
everythingals.org/research

TPN-101 ALS Clinical Trial

Our Guest Speaker, Andrew Satlin, M.D., Chief Medical Officer of Transposon Therapeutics, will give a brief overview of the of the TPN-101 clinical trial for patients with ALS and the C9orf72 mutation. This will be followed by Q&A.


DO NOT Miss Another Event, Subscribe to our Channel:
youtube.com/c/everythingals
TPN-101 Clinical Trial: for ALS & the C9orf72 Mutation - an Overview of the Trial plus Q&AGene & Cell Therapy ALS Trial: Transplanting stem cells into the motor cortex of patients with ALSFast-Tracking Discovery in ALS:Collaboration, Innovation, and Open ScienceStories and Innovation in ALS Episode# 9: A Tale of an ALS Reversal with McFinn LovereDr. Ostrow discusses precision medicine in ALS2024 ALS Reversals Update by Dr. Richard Bedlack M.D., Ph.D2022 Outlook for ALSHarnessing The Power of Citizen Research By Mcfinn Lovere, Dave Shulman Michael Thayer Janie GobeliHonoring All Who Served. Help to Advance Treatments for ALSThe ALS Gene Carrier Study | Detecting Early Motor & Speech Changes in ALSPhase 2b Study Readouts - Shifting the PARADIGM by Mr.Alon Ben-NoonHoliday Tips and Tricksfeaturing by McFinn, Heidi, and the Ahluwalia Family
Everything ALS |

TPN-101 Clinical Trial: for ALS & the C9orf72 Mutation - an Overview of the Trial plus Q&A

SHARE TO X SHARE TO REDDIT SHARE TO FACEBOOK WALLPAPER